Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 12/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 12/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2138527 | 0.78 | CHRM2 (0.55) | CHRM2CHRM3 | |
| SCHEMBL2142563 | 0.76 | CHRM2 (0.55) | CHRM2CHRM3 | |
| SCHEMBL2142187 | 0.72 | CHRM2 (0.69) | CHRM2CHRM3 | |
| SCHEMBL18719631 | 0.72 | MGLL (0.58) | CHRM2CHRM3MGLLSIGMAR1OPRM1 | |
| SCHEMBL13850447 | 0.69 | KDM4E (0.41) | ALDH1A1 | |
| SCHEMBL17319006 | 0.68 | SIGMAR1 (0.53) | CHRM2CHRM3MGLLSIGMAR1OPRM1 | |
| SCHEMBL17318952 | 0.68 | SIGMAR1 (0.58) | CHRM2MGLLSIGMAR1OPRM1KCNH2 | |
| SCHEMBL20025015 | 0.68 | MGLL (0.36) | CHRM2CHRM3MGLLSIGMAR1KCNH2 | |
| SCHEMBL2141024 | 0.67 | CHRM2 (0.49) | CHRM2CHRM3MGLL | |
| SCHEMBL26552039 | 0.67 | MGLL (0.60) | CHRM2CHRM3MGLLSIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | CHRM2 3668/4885CHRM3 4265/4885MGLL 4101/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | CHRM2 2419/4885CHRM3 2714/4885MGLL 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.